Intellia Therapeutics (NASDAQ:NTLA) Sets New 12-Month Low – Time to Sell?

Intellia Therapeutics, Inc. (NASDAQ:NTLA)’s stock price hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $9.51 and last traded at $9.54, with a volume of 247828 shares changing hands. The stock had previously closed at $9.71.

Wall Street Analysts Forecast Growth

NTLA has been the topic of a number of research analyst reports. William Blair reiterated a “neutral” rating and set a $14.00 price target on shares of Intellia Therapeutics in a report on Monday, November 18th. Barclays decreased their target price on shares of Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. Royal Bank of Canada reiterated an “outperform” rating and set a $54.00 price target on shares of Intellia Therapeutics in a report on Thursday, September 19th. Canaccord Genuity Group restated a “buy” rating and issued a $90.00 price objective on shares of Intellia Therapeutics in a report on Tuesday, November 19th. Finally, BMO Capital Markets reduced their target price on shares of Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a research note on Friday, January 10th. One research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.06.

Intellia Therapeutics Trading Down 2.7 %

The stock has a market cap of $962.48 million, a price-to-earnings ratio of -1.74 and a beta of 1.83. The firm has a fifty day simple moving average of $13.43 and a 200 day simple moving average of $18.69.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.03. The business had revenue of $9.10 million during the quarter, compared to the consensus estimate of $8.28 million. The business’s revenue was down 24.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.38) EPS. On average, equities analysts expect that Intellia Therapeutics, Inc. will post -5.11 earnings per share for the current year.

Insider Activity at Intellia Therapeutics

In other news, CEO John M. Leonard sold 26,807 shares of the company’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the sale, the chief executive officer now directly owns 941,115 shares of the company’s stock, valued at $11,462,780.70. This represents a 2.77 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 28,735 shares of company stock valued at $349,909 in the last 90 days. 3.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Intellia Therapeutics

Several large investors have recently modified their holdings of NTLA. EverSource Wealth Advisors LLC raised its stake in shares of Intellia Therapeutics by 763.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock valued at $39,000 after purchasing an additional 1,550 shares during the period. Eastern Bank acquired a new stake in Intellia Therapeutics in the 3rd quarter valued at $41,000. Values First Advisors Inc. bought a new stake in Intellia Therapeutics during the 3rd quarter worth about $54,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Intellia Therapeutics by 27.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock worth $77,000 after buying an additional 794 shares during the last quarter. Finally, KBC Group NV grew its holdings in shares of Intellia Therapeutics by 37.3% in the 3rd quarter. KBC Group NV now owns 3,753 shares of the company’s stock valued at $77,000 after acquiring an additional 1,020 shares in the last quarter. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.